MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Начало・Списък с акции・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

16.1 -3.19

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

16.61

Ключови измерители
By Trading Economics
Приходи	111M 144M
Продажби	9.2M 260M
P/E Средно за сектора	12.213 63.778
EPS	0.86
Марж на печалбата	55.37
Служители	653
EBITDA	-19M 12M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+57.28% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-254M 2.9B
Предишно отваряне	19.29
Предишно затваряне	16.1

Настроения в новините

By Acuity

33%

67%

106 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

16.28 / 17.1 Подкрепа & съпротива

ACADIA Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2025 г., 23:04 ч. UTC

Топ новини

JPMorgan Raises Risk of U.S., Global Recession to 60%

3.04.2025 г., 22:40 ч. UTC

Значими двигатели на пазара

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3.04.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3.04.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3.04.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3.04.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3.04.2025 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 21:43 ч. UTC

Топ новини

Печалби

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.04.2025 г., 20:43 ч. UTC

Пазарно говорене

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3.04.2025 г., 20:34 ч. UTC

Топ новини

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3.04.2025 г., 20:23 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3.04.2025 г., 19:21 ч. UTC

Пазарно говорене

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3.04.2025 г., 19:15 ч. UTC

Пазарно говорене

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Gold Drops In Tariff Fallout -- Market Talk

3.04.2025 г., 18:39 ч. UTC

Пазарно говорене

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3.04.2025 г., 18:38 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 18:30 ч. UTC

Топ новини

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3.04.2025 г., 18:20 ч. UTC

Пазарно говорене

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3.04.2025 г., 18:18 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:17 ч. UTC

Пазарно говорене

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3.04.2025 г., 18:04 ч. UTC

Пазарно говорене

US Sees More Job Openings in Construction, Transportation -- Market Talk

3.04.2025 г., 17:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

ACADIA Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

57.28% нагоре

12-месечна прогноза

Среден 26.14 USD 57.28%

Висок 37 USD

Нисък 18 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за ACADIA Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на ACADIA Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.28 / 17.1Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

106 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.